INTRODUCTION
Shiragami and colleagues [1] have presented a cost-effectiveness model of the use of routine pneumococcal vaccination in infants in Japan using the 10-valent pneumococcal conjugate vaccine (PCV10) and the 13-valent pneumococcal conjugate vaccine (PCV13). In this analysis, the authors concluded that the routine use of PCV10 was more cost-effective than PCV13. While the analysis applies modeling methodologies that are sound, many of the assumptions presented in the paper are inconsistent with current published scientific evidence, specifically those regarding PCV13 effectiveness against serotype 3, PCV10 effectiveness against pneumonia, PCV10
effectiveness against otitis media, PCV10 crossprotection against serotypes not contained in the vaccine (serotypes 6 and 19A), and herd effects. We challenge these assumptions using previously conducted studies and data in the public domain. Kingdom following the introduction of PCV13 in the UK National Immunisation Program [16] .
In other countries with robust surveillance systems, positive point estimates for serotype 3 have been presented [13, 17, 18] . Although it is true that positive point estimates for serotype 3 effectiveness took longer to reach statistical significance [13] , it is clear that PCV13 cannot be considered ineffective against serotype 3. Furthermore, the confidence intervals observed for NTHi were wide, and methodological flaws were observed, such as the extraordinarily low number of otitis media cases and the low number of bacteriologically confirmed otitis media cases [25] . Two studies of all-cause AOM conducted in Finland, one assessing PCV7 and the other assessing PCV10, each found nearly the same reduction in AOM, supporting that there was no added benefit in reduction of all-cause AOM with PCV10 [26, 27] . Since the United States transitioned from PCV7 to PCV13, an additional reduction in all-cause AOM has been reported in children\2 years of age, supporting an incremental benefit of PCV13 in the reduction of AOM consistent with its broader serotype coverage [28] . As highlighted previously [2, 29] , and again in the model of Shiragami and colleagues, AOM is erroneously responsible for the majority of modeled cost differences reported between the 2 vaccines.
EFFECTIVENESS AGAINST PNEUMONIA
Based on the available information and the fact that protection against disease is based on the serotypes contained in the vaccine, we believe that using an effectiveness analysis that is proportional for the serotype coverage of PCV10 and PCV13 is the most appropriate approach.
CROSS-PROTECTION AGAINST SEROTYPES NOT INCLUDED IN PCV10
Early studies relied on PCV7 data to extrapolate effectiveness of the higher valent vaccines.
However, after 5 years of use, a vaccine should be able to support assumptions with evidence.
Considering that PCV7 and PCV10 are manufactured using different carrier proteins [36, 37] . Combined with the lack of confirmation of any 19A cross-protection in countries where PCV10 is used in a national program [38, 39] , it is inappropriate to use crossprotection against 19A as a base case assumption.
HERD EFFECTS
The analyses by Shiragami and colleagues do not include any assumption regarding indirect or herd effects. Herd effects are critical for evaluating the full public health impact of vaccines. Each case of pneumococcal disease that is prevented indirectly provides an economic and health benefit while imposing no additional costs, making herd effects a powerful driver of value. For PCV13, indirect effects have been demonstrated and reported for persons older than 5 years of age in countries with pediatric immunization programs and high vaccine uptake [13, 40] . This has not been the case for PCV10, as has been clearly demonstrated in data from Finland and Chile [41, 42] .
SUMMARY
Because all important assumptions used in the model are simultaneously biased toward PCV10, the model results are erroneous and misleading.
Routine infant pneumococcal vaccination in Japan would undoubtedly bring substantial reductions in morbidity and mortality.
However, given the current epidemiologic landscape in Japan and the current evidence, the clinical and economic gains from the use of PCV13 would, undoubtedly, far exceed those potentially observed from the use of PCV10. We urge those who conduct, critique, and consider cost-effectiveness studies to evaluate the strength of the evidence of clinical claims for the products and the influence these assumptions have on the overall findings. In addition, when performing economic predictive modeling, it is critical to provide a balanced perspective by weighing the strengths and weaknesses of all available data to construct the base case analysis. 
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